Table 1 (abstract P038) Early treatment outcomes and ICU length of stay in the STRIVE Trial (mITT population)

Parameter	Rezafungin 400/400 mg (N = 76)	Rezafungin 400/200 mg (N = 46)	Caspofungin 70/50 mg (N = 61)
Negative blood culture at 24 h, % (n/N)	74.1 (43/58)	73.7 (28/38)	54.0 (27/50)
Negative blood culture at 48 h, % (n/N)	86.0 (49/57)	86.1 (31/36)	65.3 (32/49)
Mycological Cure (Day 5), % (n)	65.8 (50)	76.1 (35)	62.3 (38)
Overall success (Day 5), % (n)	55.3 (42)	73.9 (34)	55.7 (34)
ICU patients, % (n)	31.6 (24)	39.1 (18)	37.7 (23)
Median length of stay in the ICU, days (Min, Max)	13.0 (1–79)	13.0 (2–48)	18.0 (1–61)